论文部分内容阅读
目的探讨奥曲肽联合前列地尔治疗肝肾综合征的疗效及安全性。方法将72例肝肾综合征患者按照入院顺序分为观察组36例和对照组36例,两组给予常规治疗,对照组在此基础上加用前列地尔;治疗组在对照组基础上加用奥曲肽。两组均治疗14d,评估临床疗效及不良反应。结果治疗组总有效率明显高于对照组,两组有效率比较具有统计学意义(χ2=4.30,P<0.05)。所有患者不良反应均可耐受,且未见严重不良反应发生。结论奥曲肽联合前列地尔治疗肝肾综合征能够明显改善患者的肾功能,降低门静脉压力,且具有良好安全性。
Objective To investigate the efficacy and safety of octreotide combined with alprostadil in the treatment of hepatorenal syndrome. Methods 72 patients with hepatorenal syndrome were divided into observation group (36 cases) and control group (36 cases) according to the order of admission. The two groups were given routine treatment, while the control group was treated with alprostadil. The treatment group was added on the basis of control group With octreotide. Both groups were treated for 14 days to evaluate the clinical efficacy and adverse reactions. Results The total effective rate in the treatment group was significantly higher than that in the control group, and the effective rates in the two groups were statistically significant (χ2 = 4.30, P <0.05). All patients can tolerate adverse reactions, and no serious adverse reactions occurred. Conclusion Octreotide combined with alprostadil in the treatment of hepatorenal syndrome can significantly improve renal function, reduce portal pressure, and has good safety.